Clinical Trial ANRS-Quatuor
This trial has been announced by ANRS. Initially planned to start late 2016, it has been moved towards the end of 2017 ... That delay for what could have been the simple sequel, on a larger scale, of ANRS-4D
Well ... We'll start follow up
Comments
Anonymous 19 August 2017
Hello everybody,
I am under Stribild(tm) for 3 years, I just switched for Genvoya(tm) yesterday, as part of a trial funded by Gilead (without great surprise !!) and run at Institut Pasteur.
I asked to participate in the Quatuor Trial
They have answered: not possible to be in two trials and that must be under the same treatment for 2 years !! Are they under influence?
I begin to believe it and my confidence in the doctors decreases, I think more and more to join the team at Garches, if possible.
I wanted to share my experience on this blog which opened my eyes
Thank you, Charles-Edouard!
I am under Stribild(tm) for 3 years, I just switched for Genvoya(tm) yesterday, as part of a trial funded by Gilead (without great surprise !!) and run at Institut Pasteur.
I asked to participate in the Quatuor Trial
They have answered: not possible to be in two trials and that must be under the same treatment for 2 years !! Are they under influence?
I begin to believe it and my confidence in the doctors decreases, I think more and more to join the team at Garches, if possible.
I wanted to share my experience on this blog which opened my eyes
Thank you, Charles-Edouard!
Charles-Edouard! 19 August 2017
Stritbild (tm) / Genvoya (tm) will be tested in Quatuor ... Quatuor is the sequel to ANRS-4D, itself an ICCARRE sequel, so it advances on a path already cleared.
But for Strilbild (tm) / Genvoya (tm) I have no knowledge that there is only one patient to have attempted the reduction 4/7!
And they want to go direct. It's amazingly intrepid
This time, it is perhaps not so bad to pass one's turn.
Join the Garches' team? It's a good idea. Begin to get in touch, and switch home after your trial is finished.
They make the 1/7 (at least Leibowitch does...). With Elvitegravir? Not to my knowledge. Good continuation and keep us posted
But for Strilbild (tm) / Genvoya (tm) I have no knowledge that there is only one patient to have attempted the reduction 4/7!
And they want to go direct. It's amazingly intrepid
This time, it is perhaps not so bad to pass one's turn.
Join the Garches' team? It's a good idea. Begin to get in touch, and switch home after your trial is finished.
They make the 1/7 (at least Leibowitch does...). With Elvitegravir? Not to my knowledge. Good continuation and keep us posted
Anonymous 19 August 2017
Indeed, Genvoya(tm) is included in the scope of the trial ... Why not ... It contains Truvada(tm) which lifespan is longer than Elvitegravir ...
Charles-Edouard! 19 August 2017
Why not ? If Strilbild (tm) / Genvoya (tm) works in 4/7 it will be a big step forward for patients.
When they launched ANRS-4D, direct to 4D, it had alarmed me a bit, being rather attached to the progressivity.
I had not integrated that the second batch of patients in ICCARRE-2, about 40 patients, had already experienced 4D direct: so the experimental clinicians had a solid experience behind them ... My fears were unfounded.
Before doing 4/7 direct with RAL, there are 3 pilot patients at Leibowitch ... Before doing 4/7 (direct?) With DTG (triumeq) there are some community testimonials ... but with EVG, Nothing ... And, EVG, alone, without Cobi, is 2 hours of half life, and, on Monday, at resuption, there is no Cobi of the day before, in the liver.
It would have been worthwhile to have a little experimentation beforehand ... Whatever ...
This result does not matter to us: Strilbild (tm) / Genvoya (tm) leads to a loss of opportunity for the patient (Mono-DTG prohibited) , So there is a problem, and if anyone wants to take interest in the weekly take (the subject of this blog) and bring elements in favor of this perspective (Strilbild (tm) / Genvoya (tm) as once Weekly), well ... Either ... We'll see at that time. In the meantime, for those who are interested in weekly intake, there are sufficient avenues available today to avoid risk.
Leibowitch says to have 88 patients at 2/7 (or 1/7): none with Elvitegravir!
The users of Strilbild (tm) / Genvoya (tm) are well in trouble: and when they ask a question on this blog, I find it difficult to enlighten them with a trial already done, so I do not reply: I leave that to others ...
When they launched ANRS-4D, direct to 4D, it had alarmed me a bit, being rather attached to the progressivity.
I had not integrated that the second batch of patients in ICCARRE-2, about 40 patients, had already experienced 4D direct: so the experimental clinicians had a solid experience behind them ... My fears were unfounded.
Before doing 4/7 direct with RAL, there are 3 pilot patients at Leibowitch ... Before doing 4/7 (direct?) With DTG (triumeq) there are some community testimonials ... but with EVG, Nothing ... And, EVG, alone, without Cobi, is 2 hours of half life, and, on Monday, at resuption, there is no Cobi of the day before, in the liver.
It would have been worthwhile to have a little experimentation beforehand ... Whatever ...
This result does not matter to us: Strilbild (tm) / Genvoya (tm) leads to a loss of opportunity for the patient (Mono-DTG prohibited) , So there is a problem, and if anyone wants to take interest in the weekly take (the subject of this blog) and bring elements in favor of this perspective (Strilbild (tm) / Genvoya (tm) as once Weekly), well ... Either ... We'll see at that time. In the meantime, for those who are interested in weekly intake, there are sufficient avenues available today to avoid risk.
Leibowitch says to have 88 patients at 2/7 (or 1/7): none with Elvitegravir!
The users of Strilbild (tm) / Genvoya (tm) are well in trouble: and when they ask a question on this blog, I find it difficult to enlighten them with a trial already done, so I do not reply: I leave that to others ...
Legoeland 19 August 2017
Thank you for your answer.
It is once again focused exclusively on the premise that Dolutegravir in monotherapy and the least possible intakes per week is the grail.
This is the credo of your blog.
The Quatuor trial was just mentioned in this thread. That it also concerns patients who take Genvoya(tm) is good news, this combination (or the old Stribild) is one of the most prescribed in France.
Quatuor, if I understood correctly, will not test Elvitegravir but the 4 products contained in the Genvoya (tm).
The possibility of switching to Dolu is of great concern to you in the context of a supposed Absolutegravir, but other routes exist in the event of failure, including Bictegravir, which seems to have, according to a recent study, a different design from the EVG / RAL. Good news.
It is once again focused exclusively on the premise that Dolutegravir in monotherapy and the least possible intakes per week is the grail.
This is the credo of your blog.
The Quatuor trial was just mentioned in this thread. That it also concerns patients who take Genvoya(tm) is good news, this combination (or the old Stribild) is one of the most prescribed in France.
Quatuor, if I understood correctly, will not test Elvitegravir but the 4 products contained in the Genvoya (tm).
The possibility of switching to Dolu is of great concern to you in the context of a supposed Absolutegravir, but other routes exist in the event of failure, including Bictegravir, which seems to have, according to a recent study, a different design from the EVG / RAL. Good news.
Charles-Edouard! 19 August 2017
The blog is dedicated, as the name suggests, to the weekly dose; During 17-18 we will gradually move to remission (maintained); I only discuss the other strategies insofar as they are a gateway to 1/7; It takes me enough of my time not to scatter too much; For other strategies, there is the Morlat report.
Certainly, the 4/7 with EVG / co (ie Stribild(tm) or Genvoya(tm)) will be tested in ANRS: it will be, if it works, good news for those who take it, especially since it is the doctor who prescribed ; The patient, a little naive, can not oppose it; What if it does not work? This will be good news ... For others ...
The split between patients who use Gilead products and those who use others (eg ViiV) is inevitable: it is the result of Gilead's deliberate policy of keeping his patients captive. From the point of view of the industrialist or the investor, it is legitimate, it is even a very good strategy. For the patient (or the payer) it is a little less.
On the day EVG is shown as a gateway to Monotherapy and / or 1/7, EVG will have its place here. Besides, if you wish, you can take the time to discuss with these patients who hope to go beyond Stribild / Genvoya in 7/7, even in 4/7.
For anyone who is interested in remission (initially maintained at 1/7 for the time being) EVG has no interest, and Bictegravir is a simple copy of DTG, which will only be marketed 4-5 years. We'll be already far away !!!
For me who is in 1/7 (100 mg DTG + 600 mg 3TC), as for all those, who with Leibowitch, are in 2/7 or 1/7, without EVG, what can bring Stribild or Genvoya to the 4/7? Who will want to start in Stribild / Genvoya in 3/7? Huh? Who ? Is there even a single patient under Stibild 4/7? Even 5/7 ?? Even 6/7 ???
For the Septist patient (7/7) there are other unexplored tracks like Atripla half-pill (7/7); It is potentially interesting, but not from a perspective of remission.
The algorithm works recursively in one direction: one can not hope for remission without having managed the remission maintained (1/7; 1/15) one can not hope to succeed the 1/7 without having passed the 4/7. Successfully completing the 4/7 is a prerequisite. It is only enough if we get to the next step: the 3/7 for example ... Gilead's policy is to reduce the doses in the same tablet, while maintaining the price (Hi, hi, hi ...), without ever letting a bi or a mono.
Only Tivicay can allow it ... ViiV did not put the DTG (solo) on the market of cheerfulness of heart, they forced and forced it (by Gilead, which takes the place available and dominates the market)
For the rest, it does not seem to me that Stribild / Genvoya has made a remarkable breakthrough on the French market; I have no figures.
I hope that my readers will understand that this blog is not a chat room for Stibild / Genvoya users, except to prove that it has an interest for 1/7. They will be satisfied with the other places of discussion, for benign strategies. Here we are hard-core ;-)
The quest for remission maintained (1/7) is a long path ... It may not be for everyone ... What can I do?
And if you want to write a note with your words, your vision of things, while remaining in the subject (1/7 ...), you are a thousand times welcome: we willingly accept guest posts!
Certainly, the 4/7 with EVG / co (ie Stribild(tm) or Genvoya(tm)) will be tested in ANRS: it will be, if it works, good news for those who take it, especially since it is the doctor who prescribed ; The patient, a little naive, can not oppose it; What if it does not work? This will be good news ... For others ...
The split between patients who use Gilead products and those who use others (eg ViiV) is inevitable: it is the result of Gilead's deliberate policy of keeping his patients captive. From the point of view of the industrialist or the investor, it is legitimate, it is even a very good strategy. For the patient (or the payer) it is a little less.
On the day EVG is shown as a gateway to Monotherapy and / or 1/7, EVG will have its place here. Besides, if you wish, you can take the time to discuss with these patients who hope to go beyond Stribild / Genvoya in 7/7, even in 4/7.
For anyone who is interested in remission (initially maintained at 1/7 for the time being) EVG has no interest, and Bictegravir is a simple copy of DTG, which will only be marketed 4-5 years. We'll be already far away !!!
For me who is in 1/7 (100 mg DTG + 600 mg 3TC), as for all those, who with Leibowitch, are in 2/7 or 1/7, without EVG, what can bring Stribild or Genvoya to the 4/7? Who will want to start in Stribild / Genvoya in 3/7? Huh? Who ? Is there even a single patient under Stibild 4/7? Even 5/7 ?? Even 6/7 ???
For the Septist patient (7/7) there are other unexplored tracks like Atripla half-pill (7/7); It is potentially interesting, but not from a perspective of remission.
The algorithm works recursively in one direction: one can not hope for remission without having managed the remission maintained (1/7; 1/15) one can not hope to succeed the 1/7 without having passed the 4/7. Successfully completing the 4/7 is a prerequisite. It is only enough if we get to the next step: the 3/7 for example ... Gilead's policy is to reduce the doses in the same tablet, while maintaining the price (Hi, hi, hi ...), without ever letting a bi or a mono.
Only Tivicay can allow it ... ViiV did not put the DTG (solo) on the market of cheerfulness of heart, they forced and forced it (by Gilead, which takes the place available and dominates the market)
For the rest, it does not seem to me that Stribild / Genvoya has made a remarkable breakthrough on the French market; I have no figures.
I hope that my readers will understand that this blog is not a chat room for Stibild / Genvoya users, except to prove that it has an interest for 1/7. They will be satisfied with the other places of discussion, for benign strategies. Here we are hard-core ;-)
The quest for remission maintained (1/7) is a long path ... It may not be for everyone ... What can I do?
And if you want to write a note with your words, your vision of things, while remaining in the subject (1/7 ...), you are a thousand times welcome: we willingly accept guest posts!
EllsworthJJ August 30, 2017
Hi wonderful hindering the ongoing big pharma onslaught!!!!!!!!
For me who is in 1/7 (100 mg DTG + 600 mg 3TC). Question why not 2/7 2x (50 mg DTG + 300 mg 3TC)?in regards, recent change to DTG 3TC w/Prizicobo.
How soon 1/7 100mg DTG?
Good luck, best wishes.
Also HPV vaccine for reducing high HPV cancer rates
Thank you
NP Anal Dysplasia Clinic Continued FYI,
Furthermore, exciting new data in the field of therapeutic vaccines against HPV will be discussed as this may form a more durable and clinically successful therapeutic approach for the treatment of HPV-induced high-grade lesions in HIV-positive subjects on HAART CONCLUSIONS:
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men.
Palefsky JM[Author] HPV Vaccine PubMed https://www.ncbi.nlm.nih.gov/pubmed
Human papillomavirus anogenital disease in HIV-infected individuals. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/15842614
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/16691066
The HPV vaccines interestingly helps in hiv+ And hiv- In both with/without cancers or precancers in studies
NP Thank-you very much!!!!!!!
The terrible roll out of highly effective PREP & PEP speaks for itself.
The hard to get HPV vaccine to prevent cancers speaks for itself vs chemo & radiation speaks for itself!!!!!!!!
Any thoughts about the high rates of cancers??
For me who is in 1/7 (100 mg DTG + 600 mg 3TC). Question why not 2/7 2x (50 mg DTG + 300 mg 3TC)?in regards, recent change to DTG 3TC w/Prizicobo.
How soon 1/7 100mg DTG?
Good luck, best wishes.
Also HPV vaccine for reducing high HPV cancer rates
Thank you
NP Anal Dysplasia Clinic Continued FYI,
Furthermore, exciting new data in the field of therapeutic vaccines against HPV will be discussed as this may form a more durable and clinically successful therapeutic approach for the treatment of HPV-induced high-grade lesions in HIV-positive subjects on HAART CONCLUSIONS:
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men.
Palefsky JM[Author] HPV Vaccine PubMed https://www.ncbi.nlm.nih.gov/pubmed
Human papillomavirus anogenital disease in HIV-infected individuals. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/15842614
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/16691066
The HPV vaccines interestingly helps in hiv+ And hiv- In both with/without cancers or precancers in studies
NP Thank-you very much!!!!!!!
The terrible roll out of highly effective PREP & PEP speaks for itself.
The hard to get HPV vaccine to prevent cancers speaks for itself vs chemo & radiation speaks for itself!!!!!!!!
Any thoughts about the high rates of cancers??
Charles-Edouard! August 30, 2017
Many thanks for your comment!
The blog's main language is French, and we are working hard to keep up with the English version.
Discussion are also translated; hence your comment will appear in French in the French version.
The French version has more, yet, not so much more since a number of documents are tranlations from English original documents;
If you are questionning about my own strategy, I am currently working on validating 2x 50 mg DTG + 300 mg 3TC, 1/7 (this will take another 6 months)
Once validated, I will have to make a decision of either stay with it, as it is real cool, move on to 2x50 mg DTG (1/7) or keep this 100 mg DTG + 300mg 3TC and explore forward into the 1/9, 1/15, as I did before and reported here:
https://once-weekly-hiv-therapies.blogspot.fr/2017/05/beyond-17.html
The French version also provides an outlook/list of the 100+ known patients under 2/7 (or 1/7); We are working on Full patients profile and testimonies. This should come later this year or in 2018.
The use of DTG + one IP (darunavir or atanazavir) as 4/7 (and beyond) is currently being explored. Dr Lanzafame has published early results; others are working on it, but we cannot publish here until we get clearance from clinicians/authors/patients.
The new trial Dualis is of course of interest: https://clinicaltrials.gov/ct2/show/NCT02486133
and thank you for pointing out. There is an intense debate, here, on which agent should be used (if any...) along with DTG
I can not comment on cancers. As far as I know, there has not been a single cancer case associated with Short Cycle in our French cohort (ca. 200 patients) I will nonetheless try to get expert opinion on this matter.
Virus associated cancers, such as anal cancers, have been reported. A through look at the Swiss cohort showed no such cancers in the non-smoker group
Please kindly keep us posted on your own progress and consider helping us this testimonies or blog posts or translation/rewriting, if you can.
The blog's main language is French, and we are working hard to keep up with the English version.
Discussion are also translated; hence your comment will appear in French in the French version.
The French version has more, yet, not so much more since a number of documents are tranlations from English original documents;
If you are questionning about my own strategy, I am currently working on validating 2x 50 mg DTG + 300 mg 3TC, 1/7 (this will take another 6 months)
Once validated, I will have to make a decision of either stay with it, as it is real cool, move on to 2x50 mg DTG (1/7) or keep this 100 mg DTG + 300mg 3TC and explore forward into the 1/9, 1/15, as I did before and reported here:
https://once-weekly-hiv-therapies.blogspot.fr/2017/05/beyond-17.html
The French version also provides an outlook/list of the 100+ known patients under 2/7 (or 1/7); We are working on Full patients profile and testimonies. This should come later this year or in 2018.
The use of DTG + one IP (darunavir or atanazavir) as 4/7 (and beyond) is currently being explored. Dr Lanzafame has published early results; others are working on it, but we cannot publish here until we get clearance from clinicians/authors/patients.
The new trial Dualis is of course of interest: https://clinicaltrials.gov/ct2/show/NCT02486133
and thank you for pointing out. There is an intense debate, here, on which agent should be used (if any...) along with DTG
I can not comment on cancers. As far as I know, there has not been a single cancer case associated with Short Cycle in our French cohort (ca. 200 patients) I will nonetheless try to get expert opinion on this matter.
Virus associated cancers, such as anal cancers, have been reported. A through look at the Swiss cohort showed no such cancers in the non-smoker group
Please kindly keep us posted on your own progress and consider helping us this testimonies or blog posts or translation/rewriting, if you can.
Hello everybody,
ReplyDeleteI am under Stribild(tm) for 3 years, I just switched for Genvoya(tm) yesterday, as part of a trial funded by Gilead (without great surprise !!) and run at Institut Pasteur.
I asked to participate in the Quatuor Trial
They have answered: not possible to be in two trials and that must be under the same treatment for 2 years !! Are they under influence?
I begin to believe it and my confidence in the doctors decreases, I think more and more to join the team at Garches, if possible.
I wanted to share my experience on this blog which opened my eyes
Thank you, Charles-Edouard!
Stritbild (tm) / Genvoya (tm) will be tested in Quatuor ... Quatuor is the sequel to ANRS-4D, itself an ICCARRE sequel, so it advances on a path already cleared.
ReplyDeleteBut for Strilbild (tm) / Genvoya (tm) I have no knowledge that there is only one patient to have attempted the reduction 4/7!
And they want to go direct. It's amazingly intrepid
This time, it is perhaps not so bad to pass one's turn.
Join the Garches' team? It's a good idea. Begin to get in touch, and switch home after your trial is finished.
They make the 1/7 (at least Leibowitch does...). With Elvitegravir? Not to my knowledge. Good continuation and keep us posted
Indeed, Genvoya(tm) is included in the scope of the trial ... Why not ... It contains Truvada(tm) which lifespan is longer than Elvitegravir ...
ReplyDeleteWhy not ? If Strilbild (tm) / Genvoya (tm) works in 4/7 it will be a big step forward for patients.
ReplyDeleteWhen they launched ANRS-4D, direct to 4D, it had alarmed me a bit, being rather attached to the progressivity.
I had not integrated that the second batch of patients in ICCARRE-2, about 40 patients, had already experienced 4D direct: so the experimental clinicians had a solid experience behind them ... My fears were unfounded.
Before doing 4/7 direct with RAL, there are 3 pilot patients at Leibowitch ... Before doing 4/7 (direct?) With DTG (triumeq) there are some community testimonials ... but with EVG, Nothing ... And, EVG, alone, without Cobi, is 2 hours of half life, and, on Monday, at resuption, there is no Cobi of the day before, in the liver.
It would have been worthwhile to have a little experimentation beforehand ... Whatever ... This result does not matter to us: Strilbild (tm) / Genvoya (tm) leads to a loss of opportunity for the patient (Mono-DTG prohibited) , So there is a problem, and if anyone wants to take interest in the weekly take (the subject of this blog) and bring elements in favor of this perspective (Strilbild (tm) / Genvoya (tm) as once Weekly), well ... Either ... We'll see at that time. In the meantime, for those who are interested in weekly intake, there are sufficient avenues available today to avoid risk.
Leibowitch says to have 88 patients at 2/7 (or 1/7): none with Elvitegravir!
The users of Strilbild (tm) / Genvoya (tm) are well in trouble: and when they ask a question on this blog, I find it difficult to enlighten them with a trial already done, so I do not reply: I leave that to others ...
Thank you for your answer.
ReplyDeleteIt is once again focused exclusively on the premise that Dolutegravir in monotherapy and the least possible intakes per week is the grail.
This is the credo of your blog.
The Quatuor trial was just mentioned in this thread. That it also concerns patients who take Genvoya(tm) is good news, this combination (or the old Stribild) is one of the most prescribed in France.
Quatuor, if I understood correctly, will not test Elvitegravir but the 4 products contained in the Genvoya (tm).
The possibility of switching to Dolu is of great concern to you in the context of a supposed Absolutegravir, but other routes exist in the event of failure, including Bictegravir, which seems to have, according to a recent study, a different design from the EVG / RAL. Good news.
The blog is dedicated, as the name suggests, to the weekly dose; During 17-18 we will gradually move to remission (maintained); I only discuss the other strategies insofar as they are a gateway to 1/7; It takes me enough of my time not to scatter too much; For other strategies, there is the Morlat report.
ReplyDeleteCertainly, the 4/7 with EVG / co (ie Stribild(tm) or Genvoya(tm)) will be tested in ANRS: it will be, if it works, good news for those who take it, especially since it is the doctor who prescribed ; The patient, a little naive, can not oppose it; What if it does not work? This will be good news ... For others ...
The split between patients who use Gilead products and those who use others (eg ViiV) is inevitable: it is the result of Gilead's deliberate policy of keeping his patients captive.
From the point of view of the industrialist or the investor, it is legitimate, it is even a very good strategy. For the patient (or the payer) it is a little less.
On the day EVG is shown as a gateway to Monotherapy and / or 1/7, EVG will have its place here. Besides, if you wish, you can take the time to discuss with these patients who hope to go beyond Stribild / Genvoya in 7/7, even in 4/7.
For anyone who is interested in remission (initially maintained at 1/7 for the time being) EVG has no interest, and Bictegravir is a simple copy of DTG, which will only be marketed 4-5 years. We'll be already far away !!!
For me who is in 1/7 (100 mg DTG + 600 mg 3TC), as for all those, who with Leibowitch, are in 2/7 or 1/7, without EVG, what can bring Stribild or Genvoya to the 4/7? Who will want to start in Stribild / Genvoya in 3/7? Huh? Who ? Is there even a single patient under Stibild 4/7? Even 5/7 ?? Even 6/7 ???
For the Septist patient (7/7) there are other unexplored tracks like Atripla half-pill (7/7); It is potentially interesting, but not from a perspective of remission.
The algorithm works recursively in one direction: one can not hope for remission without having managed the remission maintained (1/7; 1/15) one can not hope to succeed the 1/7 without having passed the 4/7. Successfully completing the 4/7 is a prerequisite.
It is only enough if we get to the next step: the 3/7 for example ... Gilead's policy is to reduce the doses in the same tablet, while maintaining the price (Hi, hi, hi ...), without ever letting a bi or a mono.
Only Tivicay can allow it ... ViiV did not put the DTG (solo) on the market of cheerfulness of heart, they forced and forced it (by Gilead, which takes the place available and dominates the market)
For the rest, it does not seem to me that Stribild / Genvoya has made a remarkable breakthrough on the French market; I have no figures.
I hope that my readers will understand that this blog is not a chat room for Stibild / Genvoya users, except to prove that it has an interest for 1/7. They will be satisfied with the other places of discussion, for benign strategies. Here we are hard-core ;-)
The quest for remission maintained (1/7) is a long path ... It may not be for everyone ... What can I do?
And if you want to write a note with your words, your vision of things, while remaining in the subject (1/7 ...), you are a thousand times welcome: we willingly accept guest posts!
Hi wonderful hindering the ongoing big pharma onslaught!!!!!!!!
ReplyDeleteFor me who is in 1/7 (100 mg DTG + 600 mg 3TC). Question why not
2/7 2x (50 mg DTG + 300 mg 3TC)?in regards, recent change to DTG 3TC w/Prizicobo.
How soon 1/7 100mg DTG?
Good luck, best wishes.
Also HPV vaccine for reducing high HPV cancer rates
Thank you
NP Anal Dysplasia Clinic Continued FYI,
Furthermore, exciting new data in the field of therapeutic vaccines against HPV will be discussed as this may form a more durable and clinically successful therapeutic approach for the treatment of HPV-induced high-grade lesions in HIV-positive subjects on HAART
CONCLUSIONS:
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men.
Palefsky JM[Author] HPV Vaccine PubMed
https://www.ncbi.nlm.nih.gov/pubmed
Human papillomavirus anogenital disease in HIV-infected individuals. - PubMed - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/15842614
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. - PubMed - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/16691066
The HPV vaccines interestingly helps in hiv+ And hiv- In both with/without cancers or precancers in studies
NP Thank-you very much!!!!!!!
The terrible roll out of highly effective PREP & PEP speaks for itself.
The hard to get HPV vaccine to prevent cancers speaks for itself vs chemo & radiation speaks for itself!!!!!!!!
Any thoughts about the high rates of cancers??
Many thanks for your comment!
DeleteThe blog's main language is French, and we are working hard to keep up with the English version.
Discussion are also translated; hence your comment will appear in French in the French version.
The French version has more, yet, not so much more since a number of documents are tranlations from English original documents;
If you are questionning about my own strategy, I am currently working on validating 2x 50 mg DTG + 300 mg 3TC, 1/7 (this will take another 6 months)
Once validated, I will have to make a decision of either stay with it, as it is real cool, move on to 2x50 mg DTG (1/7) or keep this 100 mg DTG + 300mg 3TC and explore forward into the 1/9, 1/15, as I did before and reported here:
https://once-weekly-hiv-therapies.blogspot.fr/2017/05/beyond-17.html
The French version also provides an outlook/list of the 100+ known patients under 2/7 (or 1/7); We are working on Full patients profile and testimonies. This should come later this year or in 2018.
The use of DTG + one IP (darunavir or atanazavir) as 4/7 (and beyond) is currently being explored. Dr Lanzafame has published early results; others are working on it, but we cannot publish here until we get clearance from clinicians/authors/patients.
The new trial Dualis is of course of interest:
https://clinicaltrials.gov/ct2/show/NCT02486133
and thank you for pointing out.
There is an intense debate, here, on which agent should be used (if any...) along with DTG
I can not comment on cancers. As far as I know, there has not been a single cancer case associated with Short Cycle in our French cohort (ca. 200 patients)
I will nonetheless try to get expert opinion on this matter.
Virus associated cancers, such as anal cancers, have been reported. A through look at the Swiss cohort showed no such cancers in the non-smoker group
Please kindly keep us posted on your own progress and consider helping us this testimonies or blog posts or translation/rewriting, if you can.
A follow up comment has been posted here, and published there:
Deletehttps://once-weekly-hiv-therapies.blogspot.fr/2017/09/n155h-and-domono.html
as it does not specifically relates to Quatuor